Stay updated on Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check6 days agoChange DetectedAdded the RELIVE trial publication reference to the Publications section, including the Lancet Gastroenterol Hepatol 2019 paper and its erratum/update notes. The prior entry for this publication was revised accordingly.SummaryDifference0.1%

- Check14 days agoChange DetectedAdded a 'Show glossary' option and updated the revision to v3.4.0; several metadata labels were reformatted (e.g., capitalization changes in 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act data') and older labels were removed.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.3.4 added in the page header; a minor update that does not affect core trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check35 days agoChange DetectedThe Publications section briefly added then removed the RELIVE Lancet Gastroenterol Hepatol article citation; this back-and-forth does not affect core study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check50 days agoChange DetectedAdded study locations in Ohio and Pennsylvania and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure and the previous Ohio and Pennsylvania location entries.SummaryDifference0.2%

- Check79 days agoChange DetectedPublications are described as auto-filled from PubMed, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin in Advanced Hepatocellular Carcinoma Clinical Trial page.